Estriol; the ‘Good’ Estrogen Advances and Updates in its Clinical Uses
Erin Lommen
Jay H Mead
PDF
HTML

Keywords

Cytokines
Dendritic cells
Estriol
Menopause
Multiple sclerosis
Rheumatoid arthritis
Th1 autoimmunity
PDF
HTML

Abstract

Estriol, coined the “weaker” of the three endogenous estrogens, has significant therapeutic effects, some of which are little known to clinicians. Estriol provides numerous clinical benefits, commanding the attention of researchers dating as far back as 1966 and continues to garner substantial consideration as a valuable and viable therapeutic agent. Some of the most common and effective treatments that employ estriol include: hot flashes, insomnia, skin enhancement, vaginal atrophy and reduced frequency of urinary tract infections. Most recently, estriol has shown the potential to treat individuals with Th1-mediated autoimmune illnesses, including multiple sclerosis and rheumatoid arthritis. This review article will update the clinical effects and benefits of estriol and further clarify the documented advances which support the substantial therapeutic benefits of estriol for autoimmune conditions. The availability of compounded estriol preparations will also be addressed.

PDF
HTML

References

Lemon HM, Wotiz HH, Parsons L, et al. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. J Am Med Assoc. 1966; 196:1128–36.
Head K. Estriol: safety and efficacy. Alt Med Rev. 1998; 3:101–13.
Bergink EW. Oestriol receptor interactions: their biological importance and therapeutic implications. Acta Endocrinol Suppl (Copenh). 1980; 233:S9–S16.
Lemon HM, Foley JF. Estrogens and risk of breast cancer. J Am Med Assoc. 1987; 257:2165–6.
Lemon HM. Patholphysiologic consideration in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endrocinol Suppl (Copenh). 1980; 233:17–27.
Lemon HM. Experimental basis for multiple primary carcinogenesis by sex hormones: a review. Cancer. 1977; 40(4 Suppl):1825–32.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. J Am Med Assoc. 2002; 288:321–33.
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002; 346:340–52.
Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001; 45(3):S116–24.
Speroff L. Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
Ganong WF. Review of Medical Physiology. 22nd ed. Stamford, CT: Appleton & Lange, 2005.
Lemon HM, Kumar PF, Peterson C, et al. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer. 1989; 63:1685–92.
Lemon HM, Parsons L. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. J Am Med Assoc. 1966; 196:1128–36.
MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971; 2(7730):900–2.
Yang TS, Tsan SH, Chang SP, et al. Efficacy and safety of estriol replacement therapy for climacteric women. Zhonghua Yi Xue Za Zhi (Taipei). 1995; 55:386–91.
Takahashi K, Manabe A, Okada M, et al. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas. 2000; 34:169–77.
Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995; 62:101–6.
Cheury AC, Speck NM, de Moura KF, et al. Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. Clin Exp Obstet Gynecol. 2011; 38:143–5.
Kika G, Izumi S, Mori A, et al. Beneficial aspect of oral estriol as hormone replacement therapy: consideration on bone and lipid metabolism.Tokai J Exp Clin Med. 2009; 34:92–8.
Capobianco G, Donolo E, Borghero G, et al. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2012; 285:397–403.
Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 2003; 171(11):6267–74.
Voskuhl RR, Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis: Implications for multiple sclerosis. Neuroscientist. 2001; 7:258–70.
Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002; 52:421–8.
Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells. Ann NY Acad Sci. 2010; 1183:211–21.
Kim S, Liva SM, Dalal MA, et al. Estriol ameliorates autoimmune demyelinating disease: Implications for multiple sclerosis. Neurology. 1999; 52:1230–8.
Paperfuss TL, Powell ND, McClain MA, et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol. 2011; 186:3346–55.
Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: Inhibition of transcription factor NF-κB. J Neuroimmunol. 2002; 124:106–14.
Lauritzen C. Results of a 5 year prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res. 1987; 19:579–84.
Palaszynski KM, Liu H, Loo KK, et al. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: Implications for multiple sclerosis. J Neuroimmunol. 2004; 149(1–2):84–9.
Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci 2009; 286:99–103.
Sribnick EA, Ray SK, Nowak MW, Li L, Banik NL. 17beta-estradiol attenuates glutamate-induced apoptosis and preserves electrophysiologic function in primary cortical neurons. J Neurosci Res. 2004; 76(5):688–96.
Zhao L, Wu TW, Brinton RD. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res. 2004; 1010(1–2):22–34.
Pawlak J, Brito V, Kuppers E, Beyer C. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res. 2005; 138(1):1–7.
Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer’s disease patients. J Neurochem. 2002; 80(5):807–14.
Cantarella G, Risuglia N, Lombardo G, Lempereur L, Nicoletti F, Memo M, et al. Protective effects of estradiol on TRAIL-induced apoptosis in a human oligodendrocytic cell line: evidence for multiple sites of interactions. Cell Death Differ. 2004. [PubMed] .
Sur P, Sribnick EA, Wingrave JM, Nowak MW, Ray SK, Banik NL. Estrogen attenuates oxidative stress-induced apoptosis in C6 glial cells.Brain Res. 2003; 971(2):178–88.
Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA. 2001; 98(4):1952–7.
Jover T, Tanaka H, Calderone A, Oguro K, Bennett MV, Etgen AM, et al. Estrogen protects against global ischemia-induced neuronal death and prevents activation of apoptotic signaling cascades in the hippocampal CA1. J Neurosci. 2002; 22(6):2115–24.
Murphy DD, Cole NB, Greenberger V, Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci. 1998; 18(7):2550–9.
Rudick CN, Woolley CS. Estrogen regulates functional inhibition of hippocampal CA1 pyramidal cells in the adult female rat. J Neurosci. 2001; 21(17):6532–43.
Ziehn MO, Avedisian AA, Dervin SM, et al. Estriol preserves synaptic transmission in the hippocampus during autoimmune dymyelinating disease. Lab Invest. 2012; 92(8):1234–45.
Robinson DP, Klein SL. Pregnancy and pregnancyassociated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012; 62(3):263–71.
U.S. Department of Health and Human Services. U.S. Food and Drug Administration. FDA Takes Action Against Compounded Menopause Hormone Therapy Drugs. c2008. [cited 2012 Nov 14]. Available from:http://www.fda.gov/newsevents/newsroom/pressannouncements/2008/ucm116832.htm .
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm183078.htm. Accessed July 31, 2013 .
International Academy of Compounding Pharmacists. IACP Response to FDA Actions Against BHRT. c2008 [cited 2013 Feb 13]. Available from: http://iacprx.convio.net/site/DocServer/IACP_Letter_to_FDA.pdf?docID=3441 .
Freedom Access to Natural Solutions. FDA, Wyeth, and Global Harmonization. c2008. [cited 2012 Dec 6

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.